Clinical trial
A Phase 1, Randomized, Double-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluated the Safety, Tolerability, Pharmacokinetics, Food Effect, and Pharmacodynamics of LQT-1213 in Healthy Adult Participants
NCT05759962 is registered in ClinicalTrials.gov with Thryv Therapeutics, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-blinded, Placebo-controlled, Single and Multiple Ascending Dose Study to Evaluated the Safety, Tolerability, Pharmacokinetics, Food Effect, and Pharmacodynamics of LQT-1213 in Healthy Adult Participants
- Lead sponsor
- Thryv Therapeutics, Inc.
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- September 14, 2022
- Completion date
- March 5, 2023
- Enrollment
- 50 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.